Source comparison
Thymosin Alpha-1 Lyme Disease Immune Modulation: Comparison
Thymosin Alpha-1 Enhances T-cell maturation, upregulates IL-2/IFN-α, restores Treg function PTLDS patients with documented cytokine dysregulation and low CD4+ counts 12–24 weeks (1.6mg SC twice weekly) Mechanistic plausibility with limited clinical trial data;
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- Enhances T-cell maturation, upregulates IL-2/IFN-α, restores Treg function
- PTLDS patients with documented cytokine dysregulation and low CD4+ counts
- 12–24 weeks (1.6mg SC twice weekly)
- Mechanistic plausibility with limited clinical trial data; case series show 30–42% symptom improvement
- Best suited for immune reconstitution post-antibiotic therapy. Not a pathogen-directed treatment
- Low-Dose Naltrexone (LDN)
- Modulates opioid growth factor receptor; reduces pro-inflammatory cytokines
- PTLDS patients with neuroinflammation and autoimmune symptoms
- 12+ months (1.5–4.5mg nightly)
- Moderate. Multiple observational studies in autoimmune contexts; no Lyme-specific RCTs
- Effective for symptom management but doesn't address T-cell dysfunction directly
- Intravenous Immunoglobulin (IVIG)
- Provides passive antibodies; modulates Fc receptor activity on immune cells
- Severe PTLDS with suspected autoimmune encephalitis
- Variable (2g/kg monthly for 3–6 months)
- Low for Lyme. No controlled trials; high cost and infusion site requirements limit access
- Reserved for refractory cases with neurological decline; mechanism overlaps minimally with thymosin alpha-1
- Hyperbaric Oxygen Therapy (HBOT)
- Increases tissue oxygenation; reduces anaerobic pathogen survival; modulates oxidative stress
- Lyme patients with persistent Bartonella or Babesia co-infections
- 20–40 sessions (1.5–2.0 ATA for 60–90 minutes)
- Mixed. Small trials show benefit in neurocognitive symptoms; unclear if effect is immune-mediated or pathogen-directed
- Targets tissue hypoxia and co-infections rather than immune dysregulation. Complementary to Tα1 but not substitutive